JPRN-UMIN000035828Recruiting未知
Serum soluble (pro)renin receptor concentration at initiation of hemodialysis therapy - Serum soluble (pro)renin receptor concentration at initiation of hemodialysis therapy
Moriguchi Keijinkai Hospital0 sites200 target enrollmentStarted: March 15, 2019Last updated:
Conditions
Trial Snapshot
- Phase
- 未知
- Status
- Recruiting
- Sponsor
- Enrollment
- 200
Study Overview
Brief Summary
No summary available.
Study Design
- Study Type
- Observational
Eligibility Criteria
- Ages
- 20years-old to 100years-old (—)
- Sex
- All
Inclusion Criteria
- Not provided
Exclusion Criteria
- •other than above
Investigators
Similar Trials
Not yet recruiting
Not Applicable
Serum soluble (pro) renin receptor values and analysis in patients with solid cancerparients with solid cancerJPRN-UMIN000039172department of endocrinology and hypertension tokyo women's medical university200
Not yet recruiting
Not Applicable
Serum soluble (pro) renin receptor values and analysis in patients with lower limb amputeespatients with lower limb amputeesJPRN-UMIN000039173Department of Endocrinology and Hypertension, Tokyo Women's Medical University, Tokyo, Japan20
Active, not recruiting
Phase 1
Renin-Angiotensin System Quantification in patients treated with specific medication against hypertension (Aliskiren or Candesartan)EUCTR2012-000250-55-ATMedizinische Universität Wien, Universitätsklinik für innere Medizin III
Completed
Not Applicable
Plasma renin test guided drug treatment algorithm for correcting different subtypes of hypertension in treated but uncontrolled patientsHypertension, treated but uncontrolledCirculatory SystemHypertension secondary to other renal disordersISRCTN15531697Second Hospital of Hebei Medical University (China)180
Not yet recruiting
Not Applicable
se of peptide receptor radionuclide therapy (PRRT) in neuroendocrine tumour (NET) patients in Germany – A retrospective evaluation in German centers for NETConfirmed diagnosis of GEP-NET (any localization of the primary tumour including CUP , any Grade)DRKS00031054ovartis Radiopharmaceuticals GmbH100